BioScience Managers – Page 13 – BioScience Managers

ARECOR PRESENTS POSITIVE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA-RAPID ACTING INSULIN

15th June 2020/in BioScience Managers

Link to Full Article AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp® Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting […]

ARECOR ANNOUNCES ORAL PRESENTATION OF THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING INSULIN, AT THE AMERICAN DIABETES ASSOCIATION 80TH SCIENTIFIC SESSIONS

10th June 2020/in BioScience Managers

Cambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes […]

Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update

14th May 2020/in BioScience Managers

Link to Full Article MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the first quarter of 2020 and provided a corporate and clinical update. Key First Quarter 2020 and Subsequent […]

12 May 2020 – Posting of Annual Report and Notice of AGM

12th May 2020/in BioScience Managers

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 12 May 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that […]

Audited results for the year ended 31 December 2019 and clinical development update

29th April 2020/in BioScience Managers

Link to Full Article Company funded through to Q4 2021 Patient recruitment for XF-73 Phase 2b trial temporarily paused due to COVID-19 pandemic Brighton, United Kingdom – 29 April 2020 – Destiny Pharma (“the Company”; AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global […]

Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.

30th March 2020/in BioScience Managers

Link to Full Article – Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02 MARINA DEL REY, Calif., March 30, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that, following a vote in favor […]

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update

19th March 2020/in BioScience Managers

Link to Full Article MARINA DEL REY, Calif., March 19, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the fourth quarter and full year 2019 and provided a corporate and clinical update. Key Fourth Quarter and […]

ARECOR EXTENDS MULTI-PRODUCT COLLABORATION WITH CLINICAL STAGE BIOTECH

19th March 2020/in BioScience Managers

Link to Full Article Arecor innovative product formulations applied to oncology and rare orphan diseases Cambridge, UK, 19 March 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company. Under the collaboration, Arecor […]

Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation

18th March 2020/in BioScience Managers

Link to Full Article Award to help fund a Phase 1/2 clinical trial of the company’s Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for drug-resistant respiratory infections in cystic fibrosis patients Armata to collaborate with the Cystic Fibrosis Therapeutics Development Network MARINA DEL REY, Calif., March 18, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) […]

Clinical and Business Update

3rd March 2020/in BioScience Managers

Link to Full Article Phase 2b study on track to complete recruitment in mid-2020 Earlier grant funded programs progressing to plan Company well-funded through to mid-2021 Brighton, United Kingdom – 3 March 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address […]

Pages